
News|Articles|June 6, 2017
AMRI to be Acquired by The Carlyle Group
Author(s)Pharmaceutical Technology Editors
The company will be acquired for $21.75 per share in cash.
Advertisement
On June 6, 2017, AMRI announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group for $21.75 per share in cash. The agreement was unanimously approved by AMRI's Board of Directors, which has recommended that the shareholders vote in favor of the transaction.
Closing of the transaction is subject to customary closing conditions. It is anticipated that the special meeting of AMRI's stockholders to vote on the transaction will be held in the third quarter of 2017, and if the transaction is approved, the merger would be expected to close shortly thereafter.
Source:
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Writing the Biological Script: Scaling DNA Manufacturing for the Next Generation of Therapeutics
2
Thermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Value
3
FDA Approves Pfizer’s Breast Cancer Treatment
4
Q&A: Why Pharma Deal Volume Is Down but Value Is Up
5



